Effect of New Topical Preparation for Treatment of Acne Vulgaris

• Status: Not yet recruiting
• Trial end date: 2023-10-01
• Target enrollment: 0
• Participant gender: All

Summary

We propose a randomized, double-blind control trial study to evaluate the efficacy and safety of the optimized topical combination ME of the investigated drugs in the treatment of acne vulgaris containing DAP-FLU in comparison with standard therapy of Adapalene at Mansoura University Dermatology and Andrology Outpatient Clinic.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mansoura University
• Treatments: Adapalene

Criteria

Inclusion Criteria:

1. Male and females age 12 or older

2. Clinical diagnosis of mild to moderate facial acne vulgaris defined as:

1. ≥ 5 inflammatory lesions, and;

2. ≥ 10 non-inflammatory lesions, and;

3. IGA 2-3

3. Willing to refrain from using any treatments, other than the investigational product, for acne present on the face. This includes the use of antibiotics for the treatment of acne.

4. Willing and able to provide informed consent and to comply with the study protocol.

Exclusion Criteria:

1. Women were excluded if they were pregnant, nursing, or planning a pregnancy as were men with facial hair that would interfere with the assessments.

2. Continuous or planned use of tanning booths or excessive sun exposure, in the opinion of the Investigator.

3. Treatment with systemic corticosteroids within 28 days prior to baseline.

4. Two or more active nodular lesions.

5. Use of androgen receptor blockers (such as spironolactone or flutamide) in the 7 days prior to randomization.